INVENTIVA SA - ADR
IVANASDAQTrading Snapshot
- Day Range
- $4.68 – $4.79
- 52-Week Range
- —
- Volume
- $2.28B
- Avg Volume
- $2.27B
- Shares Outstanding
- 236.3M
- Next Earnings
- Oct 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $28,785
- P/E Ratio
- —
- P/S Ratio
- 222.9x
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own IVA
- ✓High-growth profile — revenue up +14.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About INVENTIVA SA - ADR
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives
Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Read more on IVA stock here.
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the pres
Inventiva Reports No Revenue During H1, Compared To €4.5M YoY
Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic
Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 202
Cantor Fitzgerald Initiates Coverage On Inventiva with Overweight Rating
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Inventiva (NASDAQ:IVA) with a Overweight rating.
Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring
Inventiva S.A. (NASDAQ:IVA) is one of the best strong buy penny stocks to invest in now. Inventiva S.A. (NASDAQ:IVA) announced on July 9 the completion of the final step of the transactions previously announced on June 2, 2026, through the issuance of approximately 15.7 million new warrants to the European Investment Bank, along with the […]